{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:29:57Z","timestamp":1740162597187,"version":"3.37.3"},"reference-count":29,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Polypharmacy is commonly defined as the simultaneous taking of five or more drugs. Deprescribing is the process of tapering or stopping medications with the aim of improving patient outcomes and optimising current therapy, and there are several tools aiming at identifying potentially inappropriate medications, especially in the elderly. The direct involvement of patients and their caregivers in the choice and administration of drugs has long been known to be very important, but it is not usually applied. The aim of this study is to assess the knowledge of older adults about deprescription, the effect on willingness to have regular medications deprescribed and its quality-of-life outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>This study protocol comprises three phases. The first two phases will be nationwide and aim to evaluate the prevalence and patterns of polypharmacy and assess the barriers and facilitators of deprescribing perceived by older adults, as well as their willingness to have regular medications deprescribed and to self-medicate. The third and last phase will be a non-pharmacological randomised clinical study to measure older patients\u2019 acceptance to have regular medications deprescribed and related quality of life.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>The study will be conducted in accordance with the principles expressed in the Declaration of Helsinki. It has been approved by the Ethics Committee of the University of Beira Interior and Portuguese National Data Protection Commission. Study results will be published in peer-reviewed journals and presented at national and international conferences. In short, no action will be taken without written consent from patients and doctors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>&gt;<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"NCT03283735\" ext-link-type=\"clintrialgov\">NCT03283735<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2017-019542","type":"journal-article","created":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T13:21:37Z","timestamp":1531833697000},"page":"e019542","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Deprescribing in primary care in Portugal (DePil17-20): a three-phase observational and experimental study protocol"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct03283735","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4692-2003","authenticated-orcid":false,"given":"Pedro Augusto","family":"Sim\u00f5es","sequence":"first","affiliation":[]},{"given":"Luiz Miguel","family":"Santiago","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2264-7086","authenticated-orcid":false,"given":"Jos\u00e9 Augusto","family":"Sim\u00f5es","sequence":"additional","affiliation":[]}],"member":"239","published-online":{"date-parts":[[2018,7,17]]},"reference":[{"key":"2020050713385743000_8.7.e019542.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2012.02.018"},{"key":"2020050713385743000_8.7.e019542.2"},{"key":"2020050713385743000_8.7.e019542.3","first-page":"111","article-title":"Deprescribing: a new goal focused on the patient","volume":"16","author":"Machado-Alba","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"2020050713385743000_8.7.e019542.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02543.x"},{"key":"2020050713385743000_8.7.e019542.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2004.52367.x"},{"key":"2020050713385743000_8.7.e019542.6","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1984"},{"key":"2020050713385743000_8.7.e019542.7","doi-asserted-by":"publisher","DOI":"10.2165\/11319530-000000000-00000"},{"key":"2020050713385743000_8.7.e019542.8","doi-asserted-by":"publisher","DOI":"10.5694\/mja14.00146"},{"key":"2020050713385743000_8.7.e019542.9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043617"},{"key":"2020050713385743000_8.7.e019542.10","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.131568"},{"key":"2020050713385743000_8.7.e019542.11","doi-asserted-by":"crossref","unstructured":"Turner JP , Edwards S , Stanners M , et al . What factors are important for deprescribing in Australian long-term care facilities? Perspectives of residents and health professionals. BMJ Open 2016;6:e009781.doi:10.1136\/bmjopen-2015-009781","DOI":"10.1136\/bmjopen-2015-009781"},{"key":"2020050713385743000_8.7.e019542.12","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-012-9681-8"},{"key":"2020050713385743000_8.7.e019542.13","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s11096-016-0279-4","article-title":"Attitudes towards polypharmacy and medication withdrawal among older inpatients in Italy","volume":"38","author":"Galazzi","year":"2016","journal-title":"Int J Clin Pharm"},{"key":"2020050713385743000_8.7.e019542.14","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s11096-015-0147-7","article-title":"Older peoples' attitudes regarding polypharmacy, statin use and willingness to have statins deprescribed in Australia","volume":"37","author":"Qi","year":"2015","journal-title":"Int J Clin Pharm"},{"key":"2020050713385743000_8.7.e019542.15","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jamainternmed.2015.0324","article-title":"Reducing inappropriate polypharmacy: the process of deprescribing","volume":"175","author":"Scott","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2020050713385743000_8.7.e019542.16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i2893"},{"key":"2020050713385743000_8.7.e019542.17","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12386"},{"key":"2020050713385743000_8.7.e019542.18","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0492"},{"key":"2020050713385743000_8.7.e019542.19","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/bcp.12975","article-title":"The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis","volume":"82","author":"Page","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"2020050713385743000_8.7.e019542.20","doi-asserted-by":"publisher","DOI":"10.1177\/2042098611400332"},{"key":"2020050713385743000_8.7.e019542.21","doi-asserted-by":"crossref","first-page":"386","DOI":"10.5694\/mja13.00200","article-title":"The benefits and harms of deprescribing","volume":"201","author":"Reeve","year":"2014","journal-title":"Med J Aust"},{"key":"2020050713385743000_8.7.e019542.22","doi-asserted-by":"publisher","DOI":"10.1177\/2042098616651198"},{"key":"2020050713385743000_8.7.e019542.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2012.01.006"},{"key":"2020050713385743000_8.7.e019542.24","unstructured":"Duerden M , Avery T , Payne R . Polypharmacy and medicines optimisation Making it safe and sound. Kings Fund [Internet] 2013:1\u201368 http:\/\/www.kingsfund.org.uk\/publications."},{"key":"2020050713385743000_8.7.e019542.25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e256"},{"key":"2020050713385743000_8.7.e019542.26","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.12418"},{"key":"2020050713385743000_8.7.e019542.27","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-013-0106-8"},{"key":"2020050713385743000_8.7.e019542.28","doi-asserted-by":"crossref","first-page":"222","DOI":"10.20344\/amp.5717","article-title":"[Pharmacovigilance in Portugal: Activity of the Central Pharmacovigilance Unit]","volume":"28","author":"Batel-Marques","year":"2015","journal-title":"Acta Med Port"},{"key":"2020050713385743000_8.7.e019542.29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009287"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2017-019542","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T03:19:35Z","timestamp":1601090375000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2017-019542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":29,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,7,12]]},"published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1136\/bmjopen-2017-019542"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2017-019542","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}